However, two phase I clinical trials of IL-7 in patients with cancer failed to generate overt anti-tumour effects, either as a standalone treatment43 or in combination with vaccination44, despite the expected expansion of CD4+ and CD8+ T cells in IL-7 treated patients43. The gene discussed is IL7; the disease is neoplasm.